Fresh analysis reveals that individuals who stop using blockbuster weight-loss injections like semaglutide or tirzepatide tend to recover lost weight much more quickly than those who halt conventional lifestyle plans.
Findings released in a leading medical journal points out that while overweight individuals frequently drop about a fifth of their body weight while undergoing treatment, the mass comes back at an average rate of nearly a kilo each month after stopping.
"People using such treatments should be cognizant of the danger of fast rebound weight gain when the therapy concludes," warns lead investigator Dr. Susan Jebb.
This pace of regain means a reversion to original mass within about one and a half years.
Comparing Approaches
The study, which examined 37 of studies involving over 9,000 of patients, contrasted the outcomes of the injectable medications with older methods.
Researchers point out that individuals who shed pounds through diet and exercise typically see a slower creep back—perhaps 100 grams monthly—after stopping.
Understanding the Quick Rebound
Nutrition scientists propose the mechanism of the drugs is key to understanding the accelerated weight return.
The injections imitate a body's own chemical called GLP-1, which helps regulate feelings of fullness.
"Long-term administration of the hormone levels several times higher than the body's typical production could lead to the system to generate a reduced amount of its endogenous hormone, and could lessen sensitivity to its actions," explained Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this hormone supplement means appetite is unsuppressed, making binge eating far more likely."
A Chronic Condition?
Medical guidelines recommend the injections for people with obesity-related health risks, accompanied by recommended lifestyle changes.
A number of clinicians argue that, due to the significant potential of weight regain, the therapy is often ongoing.
This opinion is supported by drug manufacturers, who say that the findings "emphasize the long-term character of obesity," similar to managing diseases like high blood pressure.
User Accounts
Individuals who have stopped the medication describe a powerful return of cravings.
"I experienced a trigger flipping and I was suddenly starving," said one woman.
This difficulty is compounded if patients have not adopted permanent dietary or behavioural modifications during treatment.
Widespread Use
Recent estimates indicate that millions of people in the UK have used these injections in the last 12 months, with interest continuing to grow.
- Adoption is higher among females than men.
- The middle-aged demographic shows the highest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
Ultimately, researchers caution that while GLP-1 drugs are potent tools for shedding pounds, they are not a magic solution and lasting health benefits hinges on combined lifestyle support.
